Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The Peru tuberculosis diagnostics market was valued at USD 385.87 Million in 2025 and is expected to grow at a CAGR of 4.90%, reaching USD 622.58 Million by 2035. The market growth is driven by the decentralization of molecular diagnostic infrastructure, government investments in tuberculosis control programmes, international funding for laboratory modernization, integration of AI-assisted chest X-ray screening, expansion of rapid drug-susceptibility testing, and improved access to diagnostic services across primary healthcare facilities and underserved populations.
Compound Annual Growth Rate
4.9%
Value in USD Million
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Tuberculosis (TB) diagnosis refers to the clinical and laboratory procedures used to detect infection with Mycobacterium tuberculosis, the bacterium responsible for tuberculosis. It involves identifying the presence of the pathogen, determining whether the infection is active or latent, and assessing whether the bacterial strain is resistant to commonly used anti-TB drugs. The market was valued at USD 385.87 Million in 2025, driven by the high national burden of tuberculosis, increasing incidence of drug-resistant TB, government-led expansion of molecular diagnostic infrastructure, and rising adoption of rapid and decentralized testing technologies.
|
Analysis Type |
Factors |
Example |
|
Market Drivers |
Expansion of decentralized molecular testing and drug-resistance detection |
In April 2026, MINSA reported conducting over 100,000 rapid molecular tests using GeneXpert and Truenat technologies. |
|
Market Restraints |
Uneven diagnostic access and recurring infrastructure costs |
Limited testing facilities, specimen transportation, trained personnel, consumables, and maintenance constrain reliable diagnostic services in remote communities. |
|
Market Opportunities |
Adoption of AI-enabled imaging and molecular diagnostic technologies |
In February 2025, Peru's Ministry of Health delivered 28 AI-enabled X-ray machines and 33 TRUELAB molecular diagnostic devices with Global Fund financing. |
The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.
Expansion of Decentralized Molecular Testing and Drug-Resistance Detection to Enhance the Market Value
The expansion of rapid molecular tuberculosis diagnostics is strengthening early detection and improving access to drug-resistance testing, particularly in underserved communities. In April 2026, the Ministry of Health (MINSA) reported processing more than 100,000 rapid molecular tests using GeneXpert and Truenat technologies. Additionally, on September 16, 2026, the Global Fund confirmed Peru’s participation in an initiative to deploy nearly 3 million portable molecular TB tests across 13 countries by the end of 2026. These initiatives support decentralized diagnostics and create opportunities for market expansion.
Uneven Diagnostic Access and Last-Mile Infrastructure Market Constraints
The most important market restraint is the uneven distribution of molecular diagnostic capacity and inadequate specimen-transport infrastructure, which limit effective utilization of testing platforms outside established healthcare networks. Although decentralization is progressing, equipment availability alone does not ensure reliable testing volumes: trained personnel, consumables, maintenance, specimen logistics, and referral coordination must also be sustained. From a healthcare-financing perspective, these recurrent operating costs compete with other public-health priorities, potentially delaying procurement and limiting returns on diagnostic infrastructure investments, particularly in geographically dispersed and resource-constrained communities.
Expansion of AI-Enabled and Molecular Diagnostic Technologies to Boost the Market Growth
The adoption of advanced diagnostic technologies is creating opportunities for Peru's tuberculosis diagnostics market by improving early detection and expanding access to testing. In February 2025, Peru's Ministry of Health, with Global Fund financing, delivered 28 AI-enabled X-ray machines and 33 TRUELAB molecular diagnostic devices to healthcare facilities. These technologies support active case finding and rapid confirmation of TB, strengthening decentralized diagnostic capabilities and improving access to timely testing.
The market is witnessing several key trends, including the expansion of decentralized testing, the adoption of advanced molecular technologies, and the integration of artificial intelligence (AI) into screening programs.
Integration of AI-Assisted Screening with Portable Molecular Diagnostics to Elevate the Market Demand
The Peru tuberculosis diagnostics market is increasingly characterized by decentralized molecular testing and AI-enabled imaging to strengthen case detection, particularly in remote and underserved areas. In October 2026, Agencia Andina reported that Peru’s Ministry of Health distributed 67 portable MiniDock devices, which can diagnose tuberculosis in about 25 minutes, while expanding its national network of AI-enabled digital X-ray units to 70. These initiatives support faster screening and access to confirmatory diagnostics.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Latent Tuberculosis Diagnostics to Maintain a Leading Market Position by Disease Type
The market is segmented by disease type into pulmonary tuberculosis diagnostics, extrapulmonary tuberculosis diagnostics, and latent tuberculosis infection diagnostics. Among these, the latent tuberculosis diagnostics segment is expected to maintain a leading position, supported by the need to identify tuberculosis infections before symptoms develop and prevent their progression to active disease. The growing emphasis on early detection and preventive treatment is likely to strengthen demand for latent tuberculosis testing. This focus on identifying and managing latent infections is expected to support the segment’s continued contribution to the market.
The key features of the market report include strategic initiatives by leading players. The major companies in the market are as follows:
Qiagen develops molecular diagnostic technologies and sample preparation solutions, supporting tuberculosis detection and drug-resistance testing through its nucleic acid extraction and amplification platforms. Its product portfolio includes QuantiFERON-TB Gold Plus for latent tuberculosis infection testing and specialized molecular assays. The company serves clinical laboratories, hospitals and research institutions across international healthcare markets.
FUJIFILM operates across healthcare, medical imaging and diagnostic technologies, offering solutions for tuberculosis screening and disease detection. Its portfolio includes digital radiography systems, medical imaging equipment and AI-assisted diagnostic technologies. The company leverages its global distribution network and imaging expertise to support healthcare infrastructure, particularly in emerging markets and resource-constrained diagnostic settings.
Molbio Diagnostics specializes in portable molecular diagnostic technologies, particularly its Truenat platform, which enables decentralized tuberculosis testing. Its solutions support the detection of Mycobacterium tuberculosis and rifampicin resistance through rapid, chip-based real-time PCR technology. The company focuses on expanding molecular diagnostic accessibility across developing countries, particularly through primary healthcare facilities and mobile diagnostic networks.
Roche is a global healthcare company with extensive capabilities in molecular diagnostics, clinical laboratory automation, and infectious disease testing. Its diagnostic portfolio includes molecular testing platforms, reagents and laboratory solutions that support pathogen detection and disease surveillance. Through its international commercial infrastructure, Roche serves hospitals, reference laboratories and healthcare systems across developed and emerging markets.
Other key players in the market include Abbott, Becton, Dickinson and Company (BD), Cepheid, Eiken Chemical Co., Ltd., Thermo Fisher Scientific Inc., and Hain Lifescience GmbH.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Diagnostics
The market is characterized by increasing adoption of rapid molecular testing, particularly for early detection of Mycobacterium tuberculosis and drug-resistant strains. Government-led TB control initiatives, rising MDR-TB burden, and investments in laboratory infrastructure are strengthening demand for accurate, rapid and accessible diagnostic technologies.
Market Breakup by Disease Type
The market is driven by the substantial burden of pulmonary tuberculosis, increasing screening of high-risk populations, and the need for improved detection of extrapulmonary infections. Growing awareness of latent TB infection, particularly among household contacts, healthcare workers, and immunocompromised individuals, is further supporting demand for immunological testing and targeted diagnostic programmes.
Market Breakup by End User
Hospitals represent important diagnostic centres owing to their patient volumes, access to clinical infrastructure, and capacity to conduct confirmatory testing. Demand from diagnostic laboratories is supported by the expansion of molecular testing networks, reference laboratory capabilities, and drug-resistance analysis, while research laboratories contribute through TB surveillance, epidemiological studies, and diagnostic technology development.
This report is developed through a structured research approach combining secondary research, market assessment, and data validation:
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnostics |
|
| Breakup by Disease Type |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.